Advertisment
Sana Biotechnology announces upcoming podium presentation at ADA/IPITA 2025
Sana Biotechnology, a company focused on changing the possible for patients through engineered cells, announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP 421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking place June 20-23, 2025 in Chicago, IL.
Presentation details:
| Symposium Title: | Joint ADA/IPITA Symposium: Outpacing the Immune System—Sprinting Towards Immune Protection for Cell Replacement Therapy |
| Presentation Title: | Hypoimmune Pancreatic Islet Transplantation in Adult Subjects with Type 1 Diabetes |
| Presentation Date: | Monday, June 23, 2025 |
| Presentation Time: | 9:00 – 9:20 a.m. CT |
| Location: | W192 A-C |
